CitiusTech launches CitiusTech Knewron

IMT News Desk
IMT News Desk
· 3 min read

CitiusTech Knewron combines layers of healthcare domain context, multi-agent orchestration, and policy-based guardrails to help organisations develop AI-first value stream maps of system workflows etc

CitiusTech announced the launch of CitiusTech Knewron, a healthcare-native AI platform to design, build and operate trusted enterprise AI solutions. CitiusTech Knewron helps healthcare organisations augment, automate, and accelerate their product development initiatives with native data ingestion, healthcare-specific guardrails, optimised and fit for purpose model routing, bespoke agent-based workflows, persona-specific workbenches, and industry-standard protocol-based tool integrations. CitiusTech Knewron’s healthcare native design efficiently accelerates time-to-market, while increasing trust and explainability.

CitiusTech Knewron combines layers of healthcare domain context, multi-agent orchestration, and policy-based guardrails to help organisations develop AI-first value stream maps of system workflows, create AI augmented domain native PDLCs, and modernise legacy systems. From accelerating product development, to launching engineering agents to automating compliance audits, CitiusTech Knewron turns weeks of work into days, without compromising human oversight, safety or accuracy.

“AI is transforming how software is built, but in healthcare, context, trust, and governance are non-negotiable. CitiusTech Knewron’s guardrails, curated knowledge, and explainability make it a true enabler,” said Rajan Kohli, CEO, CitiusTech. “Enterprises can now efficiently solve for context at scale, helping product builders and technologists work with AI capabilities for complex tasks, while being assured that the software complies with healthcare regulations, and ultimately delivers solutions not just faster, but also more securely, and at higher quality.”

With CitiusTech Knewron, the company is setting the standard for how AI should be applied in healthcare. CitiusTech Knewron’s capabilities are building blocks for faster, safer, and smarter healthcare software:

  • Healthcare Domain Nativity: Ingests and codifies clinical, Payer, and administrative workflows so AI agents operate with curated, context-rich data. It also integrates with healthcare native stacks and tools through standard protocols.
  • Agentic PDLC Orchestration: A visual workflow designer, custom agent builder, and agent-to-agent orchestration to automate product discovery, development, testing, and release.
  • Policy-as-Code & Explainability: Built-in guardrails, policy enforcement, and immutable audit trails for traceability and compliance.
  • Model-agnostic Gateway & Cost Awareness: Multi-LLM support with cost-aware routing to avoid lock-in and optimize spend.
  • Enterprise Deployment Options: Supports secure deployment in customer virtual private clouds (VPCs), private clouds, or on-premises data centers to meet data-sovereignty needs.

“CitiusTech Knewron is a category-defining solution for healthcare,” added Sudhir Kesavan, COO, CitiusTech. “We believe that AI-augmented value chains and product development will need a first principles-based approach to how solutions are conceptualised and built. This is not about automating process steps but about a journey towards rearchitecting the value chain itself. Our goal is straight forward, to enable healthcare leaders to build solutions while preserving regulatory and clinical trust. With CitiusTech Knewron, healthcare and life sciences organisations can leverage the power of foundation models and unlock efficiency, speed, accuracy, and scalability to deliver better care.”

Read Next

Agenus announces closing of $141 M strategic collaboration with Zydus Lifesciences
Global News
January 20, 2026

Agenus announces closing of $141 M strategic collaboration with Zydus Lifesciences

To advance BOT+BAL and strengthen US manufacturing readiness Agenus, a leader in immuno-oncology innovation, announced the closing of its previously disclosed strategic collaboration with Zydus Lifesciences Ltd. The agreement is designed to accelerate global development and potential commercialisation of Agenus’ botensilimab and balstilimab (BOT+BAL) immunotherapy combination programme. The collaboration provides Agenus with strategic capital and […]
Article by: IMT News Desk
Venus Remedies secures marketing authorisation for Ceftazidime + Avibactam in Indonesia
Global News
January 16, 2026

Venus Remedies secures marketing authorisation for Ceftazidime + Avibactam in Indonesia

Approval marks Venus Remedies’ first anti-infective marketing authorisation in Indonesia and enables the country’s first generic entry for this critical antibiotic combination Venus Remedies has secured the marketing authorisation from the Indonesian regulatory authority for its combination antibiotic, Ceftazidime + Avibactam. This approval represents Venus Remedies’ first marketing authorization in the anti-infective segment in Indonesia […]
Article by: IMT News Desk
Wegovy pill approved in the US for weight management
Global News
December 26, 2025

Wegovy pill approved in the US for weight management

Novo Nordisk expects to launch the Wegovy pill in the US in early January 2026 Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved the Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse […]
Article by: IMT News Desk
Samsung Biologics America in agreement to acquire 100 per cent of Human Genome Sciences from GSK
Global News
December 24, 2025

Samsung Biologics America in agreement to acquire 100 per cent of Human Genome Sciences from GSK

Under the terms of the agreement, with closing anticipated toward the end of Q1 of 2026, Samsung Biologics will acquire the Rockville assets for $280 million Samsung Biologics, a leading contract development and manufacturing organization (CDMO), announced that its wholly owned US subsidiary, Samsung Biologics America, has entered into a definitive agreement to acquire 100 […]
Article by: IMT News Desk